Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Debt (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Total Debt for 16 consecutive years, with $34.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt fell 10.28% to $34.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $34.0 million, a 10.28% decrease, with the full-year FY2024 number at $37.0 million, up 1.07% from a year prior.
  • Total Debt was $34.0 million for Q3 2025 at Harvard Bioscience, down from $34.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $49.3 million in Q3 2022 to a low of $34.0 million in Q3 2025.
  • A 5-year average of $41.3 million and a median of $41.4 million in 2023 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: rose 12.38% in 2022, then decreased 21.91% in 2023.
  • Harvard Bioscience's Total Debt stood at $48.3 million in 2021, then fell by 3.12% to $46.8 million in 2022, then fell by 21.91% to $36.6 million in 2023, then increased by 1.07% to $37.0 million in 2024, then decreased by 8.09% to $34.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Total Debt are $34.0 million (Q3 2025), $34.9 million (Q2 2025), and $36.0 million (Q1 2025).